{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T13:15:24Z","timestamp":1737292524759,"version":"3.33.0"},"reference-count":28,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.5582\/ddt.2024.01086","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T22:15:05Z","timestamp":1735251305000},"page":"336-342","source":"Crossref","is-referenced-by-count":0,"title":["Long-term renoprotective effect of luseogliflozin in type 2 diabetes patients: CHikushi Anti-diabetes mellitus Trial-Lusefi (CHAT-Lu)"],"prefix":"10.5582","volume":"18","author":[{"given":"Yosuke","family":"Takamiya","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Diseases, Fukuoka University Chikushi Hospital, Fukuoka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiyori","family":"Imanaga","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Fukuoka University Chikushi Hospital, Fukuoka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, Fukuoka University Chikushi Hospital, Fukuoka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihisa","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, Fukuoka University Chikushi Hospital, Fukuoka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amane","family":"Ike","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Fukuoka University Chikushi Hospital, Fukuoka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Fukuoka University Chikushi Hospital, Fukuoka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Urata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Fukuoka University Chikushi Hospital, Fukuoka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008; 359:1565-1576.","DOI":"10.1056\/NEJMoa0806359"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Dormandy JA, Charbonnel B, Eckland DJ, <i>et al<\/i>. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366:1279-1289.","DOI":"10.1016\/S0140-6736(05)67528-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359:1577-1589.","DOI":"10.1056\/NEJMoa0806470"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290:486-494.","DOI":"10.1001\/jama.290.4.486"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373:2117-2128.","DOI":"10.1056\/NEJMoa1504720"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377:644-657.","DOI":"10.1056\/NEJMoa1611925"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mosenzon O, Wiviott SD, Cahn A, <i>et al.<\/i> Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019; 7:606-617.","DOI":"10.1016\/S2213-8587(19)30180-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Perkovic V, Jardine MJ, Neal B, <i>et al.<\/i> Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380:2295-2306.","DOI":"10.1056\/NEJMoa1811744"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, Osawa H, Taguchi A, Tanizawa Y, Tobe K, Yoshioka N. Japanese Clinical Practice Guideline for Diabetes 2019. J Diabetes Investig. 2020; 11:1020-1076.","DOI":"10.1111\/jdi.13306"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kinoshita M, Yokote K, Arai H, <i>et al.<\/i> Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb. 2018; 25:846-984.","DOI":"10.5551\/jat.GL2017"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Umemura S, Arima H, Arima S, <i>et al.<\/i> The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019; 42:1235-1481.","DOI":"10.1038\/s41440-019-0284-9"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Levey AS, Gansevoort RT, Coresh J, <i>et al<\/i>. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020; 75:84-104.","DOI":"10.1053\/j.ajkd.2019.06.009"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Makino H, Hishida A, Matsuo S. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res. 2008; 31:433-441.","DOI":"10.1291\/hypres.31.433"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375:323-334.","DOI":"10.1056\/NEJMoa1515920"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin. 2014; 30:1245-1255.","DOI":"10.1185\/03007995.2014.912983"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, <i>et al.<\/i> (1S)1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem. 2010; 53:3247-3261.","DOI":"10.1021\/jm901893x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Samukawa Y, Sata M, Furihata K, Ito T, Ueda N, Ochiai H, Sakai S, Kumagai Y. Luseogliflozin, an SGLT2 inhibitor, in Japanese patients with mild\/moderate hepatic impairment: A pharmacokinetic study. Clin Pharmacol Drug Dev. 2017; 6:439-447.","DOI":"10.1002\/cpdd.364"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Samukawa Y, Haneda M, Seino Y, Sasaki T, Fukatsu A, Kubo Y, Sato Y, Sakai S. Pharmacokinetics and pharmacodynamics of luseogliflozin, a selective SGLT2 inhibitor, in Japanese patients with type 2 diabetes with mild to severe renal impairment. Clin Pharmacol Drug Dev. 2018; 7:820-828.","DOI":"10.1002\/cpdd.456"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Suzuki Y, Kaneko H, Okada A, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Node K, Nangaku M, Yasunaga H, Komuro I. Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2022; 102:1147-1153.","DOI":"10.1016\/j.kint.2022.05.031"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003; 63:225-232.","DOI":"10.1046\/j.1523-1755.2003.00712.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021; 17:319-334.","DOI":"10.1038\/s41581-021-00393-8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol. 1999; 10:2569-2576.","DOI":"10.1681\/ASN.V10122569"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Cassis P, Locatelli M, Cerullo D, Corna D, Buelli S, Zanchi C, Villa S, Morigi M, Remuzzi G, Benigni A, Zoja C. SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight. 2018; 3:e98720.","DOI":"10.1172\/jci.insight.98720"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Boris Bikbov, Carrie Purcell, Andrew S Levey, <i>et al<\/i>. Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020; 395:709-733.","DOI":"10.1016\/S0140-6736(20)30045-3"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Tsai CW, Lin SY, Kuo CC, Huang CC. Serum uric acid and progression of kidney disease: A longitudinal analysis and mini-review. PLoS One. 2017; 12:e0170393.","DOI":"10.1371\/journal.pone.0170393"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007; 59:251-287.","DOI":"10.1124\/pr.59.3.3"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Lomonaco R, Godinez Leiva E, Bril F, <i>et al<\/i>. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: The need for systematic screening. Diabetes Care. 2021; 44:399-406.","DOI":"10.2337\/dc20-1997"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Iimura O. Insulin resistance and hypertension in Japanese. Hypertens Res. 1996; 19 Suppl 1:S1-8.","DOI":"10.1291\/hypres.19.SupplementI_S1"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/18\/6\/18_2024.01086\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T04:25:27Z","timestamp":1737174327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/18\/6\/18_2024.01086\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2024.01086","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"type":"print","value":"1881-7831"},{"type":"electronic","value":"1881-784X"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"article-number":"2024.01086"}}